Appointment dossier — Melanoma
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Melanoma
Compounds named in the cited literature for Melanoma, labeled by the strongest evidence found:
- Anti-LAG-3 antibodies — Meta-analysis
- Antibiotics, proton pump inhibitors (PPIs), and probiotics — Meta-analysis
- beta-blockers — Meta-analysis
- biopsy — Meta-analysis
- cancer vaccine therapy — Meta-analysis
- chemotherapy — Meta-analysis
- dabrafenib + trametinib — Meta-analysis
- dabrafenib and trametinib — Meta-analysis
- dabrafenib/trametinib — Meta-analysis
- darovasertib (NVP-LXS196) — Meta-analysis
- effector T-cell therapy — Meta-analysis
- encorafenib/binimetinib — Meta-analysis
- entinostat — Meta-analysis
- high-dose interferon — Meta-analysis
- immune checkpoint inhibitors — Meta-analysis
- Immune checkpoint inhibitors (CTLA-4/PD-1/PD-L1) — Meta-analysis
- ipilimumab — Meta-analysis
- ipilimumab + nivolumab — Meta-analysis
- ipilimumab or nivolumab — Meta-analysis
- ipilimumab plus nivolumab — Meta-analysis
- ipilimumab plus nivolumab — Meta-analysis
- labial reconstruction — Meta-analysis
- liver-directed regional therapies — Meta-analysis
- Mohs micrographic surgery — Meta-analysis
- mRNA-4157/V940 plus pembrolizumab — Meta-analysis
- multimodality treatment — Meta-analysis
- nivolumab — Meta-analysis
- nivolumab — Meta-analysis
- nivolumab — Meta-analysis
- nivolumab + ipilimumab — Meta-analysis
- proton technique with IMRT — Meta-analysis
- proton therapy (SFUD) — Meta-analysis
- pucotenlimab — Meta-analysis
- selumetinib; trametinib — Meta-analysis
- standard surgical excision — Meta-analysis
- surgery — Meta-analysis
- systemic glucocorticoids — Meta-analysis
- tebentafusp — Meta-analysis
- tumor-infiltrating lymphocytes (TIL) — Meta-analysis
- vemurafenib/cobimetinib — Meta-analysis
Open recruiting trials (18)
- NCT07405086 · Phase 4 — Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study (United States)
- NCT03755739 · Phase 2 / Phase 3 — Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors (China)
- NCT05522660 · Phase 3 — Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer (Italy)
- NCT07015190 · Phase 3 — Neoadjuvant Darovasertib in Primary Uveal Melanoma (United States)
- NCT05913388 · Phase 2 — GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma (United States)
- NCT04851119 · Phase 1 / Phase 2 — Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors (United States)
- NCT07230613 · Phase 2 — Neo-adjuvant Immunotherapy in Patients With Localized Melanoma (France)
- NCT04895709 · Phase 1 / Phase 2 — A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors (United States)
- NCT02621021 · Phase 2 — A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab (United States)
- NCT06560905 · Phase 2 — Preoperative Planning With PSMA-PET in Melanoma Surgery Trial (United Kingdom)
- NCT05983237 · Phase 1 / Phase 2 — Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma (China)
- NCT03819296 · Phase 1 — Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer (United States)
- NCT06022029 · Phase 1 — A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. (United States)
- NCT06910657 · Phase 1 — IDOV-Immune for Advanced Solid Tumors (United States)
- NCT06805825 · Phase 1 — A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit (United States)
- NCT07042243 — The Florida ASCENT Study (United States)
- NCT07277920 — Reflectance Confocal Microscopy and Molecular Correlation in Atypical Melanocytic Lesions (Italy)
- NCT06643286 — Evaluation of a Personalised Survivorship Care Plan App for Patients With Melanoma (Netherlands)
Most-relevant first: trials that name Melanoma, then broader trials you may still qualify for. 475 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
Questions to ask your oncologist
- I've read that Anti-LAG-3 antibodies has been studied in people for Melanoma — what's the evidence, and is it an option or available in a trial for me?
- I've read that Antibiotics, proton pump inhibitors (PPIs), and probiotics has been studied in people for Melanoma — what's the evidence, and is it an option or available in a trial for me?
- I've read that beta-blockers has been studied in people for Melanoma — what's the evidence, and is it an option or available in a trial for me?
- Of the open trials I found (for example NCT07405086), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?